Alyeska Investment Group
CAI

Alyeska Investment Group’s Caris Life Sciences CAI Stock Holding History

Alyeska Investment Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,101,071
Closed -$33.3M – 769
2025
Q3 		$33.3M Buy
1,101,071
+725,071
+193% +$23.1M 0.1% 221
2025
Q2 		$10M Buy
+376,000
New +$10.1M 0.04% 362

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alyeska Investment Group's CAI Position: Q4 2025 in Review

Alyeska Investment Group sold out of Caris Life Sciences (CAI) in Q4 2025, closing a stake of 1,101,071 shares — an estimated $33.3M sold.

Alyeska Investment Group first reported a position in CAI in Q2 2025 and held it in 2 quarters. The position peaked at $33.3M in Q3 2025. 186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • Alyeska Investment Group reported no remaining Caris Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 1,101,071 Caris Life Sciences shares in Q4 2025, an estimated $33.3M.
  • Alyeska Investment Group first reported a position in Caris Life Sciences in Q2 2025 and held it in 2 quarters.
  • Alyeska Investment Group's Caris Life Sciences position peaked at $33.3M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.